> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Researcher Restricted After Trial Misconduct
- URL: https://www.fdaweb.com/researcher-restricted-after-trial-misconduct/
- Published: 2016-05-09T12:00:00.000Z
- Updated: 2026-09-14T21:00:55.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135602

> University of Pittsburgh researcher **Kenneth Walker** has entered into a voluntary settlement agreement with HHS’ Office of Research Integrity (ORI) due to “research misconduct” associated with work supported by the National Institute of Diabetes and Digestive and Kidney Diseases. ORI found that Walker engaged in research misconduct by falsifying and fabricating data that were included in two publications, one submitted manuscript, and two grant applications.  
>  
>  
>  
> “Specifically, ORI found that respondent falsified and/or fabricated quantitative real-time polymerase chain reaction (qPCR) data to demonstrate a statistically significant or ‘trend’ of statistical difference in the expression of renal or bladder urothelium and muscle developmental markers between control and experimental (mutant) mice, when there was none,” a [notice](https://ori.hhs.gov/content/case-summary-walker-kenneth?ref=fdaweb.com) says. Walker has voluntarily agreed to have his research supervised for a period of three years, among other restrictions. He also agreed to retract or correct data in the publications.